Drug intelligence / Profile preview

CTS-2096

Development stage: Preclinical
Lead developer: Histogen
Modality: Small Molecules
Administration: Oral

Overview

CTS-2096 is a preclinical, orally bioavailable small‑molecule inhibitor of caspase‑1 being developed by Histogen for inflammatory indications driven by inflammasome activation.[1][3][5][6][9] It is described as a novel, potent, and highly selective caspase‑1 inhibitor and inflammasome pathway inhibitor, designed to reduce maturation and release of pro‑inflammatory cytokines such as interleukin‑1β (IL‑1β) and downstream inflammatory cell death processes, with the goal of treating a range of inflammatory diseases.[1][3][5][6][9]

Targets

CASP1 (Caspase-1)

Beyond the preview

Go deeper on CTS-2096.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTS-2096.

Explore the full profile